Your browser doesn't support javascript.
Annual flu shot: Does it help patients with COVID-19?
Kline, Adam; Trinh, Lily N; Hussein, Mohammad H; Elshazli, Rami M; Toraih, Eman A; Duchesne, Juan; Fawzy, Manal S; Kandil, Emad.
  • Kline A; Tulane University, School of Medicine, New Orleans, Louisiana, USA.
  • Trinh LN; Tulane University, School of Medicine, New Orleans, Louisiana, USA.
  • Hussein MH; Department of Surgery, Tulane University, School of Medicine, New Orleans, Louisiana, USA.
  • Elshazli RM; Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus University - Egypt, New Damietta, Egypt.
  • Toraih EA; Department of Surgery, Tulane University, School of Medicine, New Orleans, Louisiana, USA.
  • Duchesne J; Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Fawzy MS; Department of Surgery, Tulane University, School of Medicine, New Orleans, Louisiana, USA.
  • Kandil E; Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Int J Clin Pract ; 75(12): e14901, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1429762
ABSTRACT
AIM OF THE STUDY The impact of annual flu vaccination on the patients' clinical course with COVID-19 and the outcome were tested.

METHODS:

A total of 149 patients with COVID-19-positive admitted from March 20 to May 10, 2020, were retrospectively enrolled.

RESULTS:

Ninety-eight (65.8%) patients received at least a single annual flu shot in the last year, and fifty-one (34.2%) were never vaccinated. On presentation, vaccinated patients were more likely to present with gastrointestinal symptoms (P < .05). There were no significant differences between study groups in laboratory findings or clinical outcomes. In multivariate analysis, receiving the annual shot did not influence risk of intensive care unit admission (OR = 1.17, 95%CI = 0.50-2.72, P = .72), intubation (OR = 1.40, 95%CI = 0.60-3.23, P = .43), complications (OR = 1.08, 95%CI = 0.52-2.26, P = .83) or mortality (OR = 1.29, 95%CI = 0.31-5.29, P = .73).

CONCLUSION:

Although the benefits of the influenza vaccine for preventing disease and reducing morbidity in influenza patients are well established, no differences in outcomes for hospitalised patients with COVID-19 who received their annual influenza vaccination versus the non-vaccinated cohort were evident. There is a need for future meta-analyses, including randomised controlled studies in which the number of cases is increased to validate these findings.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Limits: Humans Language: English Journal: Int J Clin Pract Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Ijcp.14901

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Limits: Humans Language: English Journal: Int J Clin Pract Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Ijcp.14901